levodopa has been researched along with Pantothenate Kinase-Associated Neurodegeneration in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cossu, G; Floris, G; Hayflick, SJ; Melis, M; Spissu, A | 1 |
Ali, SN; Asumal, KB; Wasay, M | 1 |
Clement, F; Coubes, P; Defebvre, L; Destee, A; Devos, D; Moreau, C | 1 |
Date, ES; Schwartz, M; Seibel, MO; Zeiner, H | 1 |
Lang, AE; Provias, JP; Tuite, PJ | 1 |
Barkhatova, VP; Insarova, NG; Ivanova-Smolenskaia, IA; Markova, ED | 1 |
6 other study(ies) available for levodopa and Pantothenate Kinase-Associated Neurodegeneration
Article | Year |
---|---|
Hallervorden Spatz syndrome (pantothenate kinase associated neurodegeneration) in two Sardinian brother with homozygous mutation in PANK 2 gene.
Topics: Adult; Dibenzothiazepines; Female; Globus Pallidus; Homozygote; Humans; Italy; Levodopa; Magnetic Resonance Imaging; Male; Mutation, Missense; Pantothenate Kinase-Associated Neurodegeneration; Phosphotransferases (Alcohol Group Acceptor); Quetiapine Fumarate | 2002 |
Radiologic features of Hallervorden Spatz Disease.
Topics: Adolescent; Child; Diagnosis, Differential; Humans; Levodopa; Magnetic Resonance Imaging; Male; Pantothenate Kinase-Associated Neurodegeneration | 2002 |
Neurodegeneration with brain iron accumulation: clinical, radiographic and genetic heterogeneity and corresponding therapeutic options.
Topics: Adolescent; Brain; Brain Diseases, Metabolic; Diagnosis, Differential; DNA Mutational Analysis; Dystonia; Female; Genetic Predisposition to Disease; Humans; Iron; Iron Metabolism Disorders; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neurodegenerative Diseases; Pantothenate Kinase-Associated Neurodegeneration; Phosphotransferases (Alcohol Group Acceptor); Treatment Outcome | 2007 |
Rehabilitation of patients with Hallervorden-Spatz syndrome.
Topics: Activities of Daily Living; Adult; Carbidopa; Drug Therapy, Combination; Exercise Therapy; Humans; Levodopa; Male; Movement Disorders; Pantothenate Kinase-Associated Neurodegeneration; Patient Care Team | 1993 |
Atypical dopa responsive parkinsonism in a patient with megalencephaly, midbrain Lewy body disease, and some pathological features of Hallervorden-Spatz disease.
Topics: Adult; Antiparkinson Agents; Brain; Humans; Hypertrophy; Levodopa; Lewy Bodies; Magnetic Resonance Imaging; Male; Pantothenate Kinase-Associated Neurodegeneration; Parkinson Disease; Substantia Nigra | 1996 |
[Clinical picture and treatment of Parkinson-like syndromes of hereditary etiology].
Topics: Adolescent; Adult; Basal Ganglia Diseases; Child; Diagnosis, Differential; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Pantothenate Kinase-Associated Neurodegeneration; Parkinson Disease | 1978 |